IJMS, Vol. 27, Pages 612: The Adipokine Axis in Heart Failure: Linking Obesity, Sarcopenia and Cardiac Dysfunction in HFpEF

IJMS, Vol. 27, Pages 612: The Adipokine Axis in Heart Failure: Linking Obesity, Sarcopenia and Cardiac Dysfunction in HFpEF International Journal of Molecular Sciences doi: 10.3390/ijms27020612 Authors: Luka Komić Jelena Komić Nikola Pavlović Marko Kumrić Josipa Bukić Iris Jerončić Tomić Joško Božić Obesity, sarcopenia, and heart failure with preserved ejection fraction (HFpEF) constitute an interconnected […]

“The only thing she practices is grift”: Meet Trump’s nominee for Surgeon General

Medical experts fear President Donald Trump’s nominee for surgeon general, Casey Means, could bring her “flaky” brand of wellness influencing to the nation. Means is best known as a wellness influencer, author and entrepreneur, as well as running a company that sells glucose monitoring systems. While Means did attend medical school, she dropped out during […]

Ozempic, Wegovy Might Lower Colon Cancer Risk

WEDNESDAY, Jan. 7, 2026 — Ozempic and Wegovy might help people avoid colon cancer as well as promote weight loss or control diabetes, a new study says.People who took a GLP-1 drug were 36% less likely to get colon cancer than people who took a…

Obesity rings in New Year with Lilly-Nimbus $1.3B deal, RNAi data

Biopharma industry zeal for obesity therapeutics does not appear to be dying down any time soon, with Eli Lilly and Co. entering a $1.3 billion deal with Nimbus Therapeutics LLC for a new small molecule, and Arrowhead Pharmaceuticals Inc. rolling out phase I/IIa data of its RNAi therapeutics used in combination with Lilly’s GLP-1/GIP receptor […]